Chemed Corporation (NYSE:CHE) Receives Average Rating of “Hold” from Analysts

Chemed Corporation (NYSE:CHE) has been given an average recommendation of “Hold” by the six brokerages that are currently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $501.50.

CHE has been the subject of several recent analyst reports. Oppenheimer reduced their target price on shares of Chemed from $580.00 to $500.00 and set an “outperform” rating for the company in a research note on Friday, February 27th. Zacks Research upgraded shares of Chemed from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Royal Bank Of Canada raised their target price on shares of Chemed from $422.00 to $436.00 and gave the stock a “sector perform” rating in a research note on Monday, April 27th. Weiss Ratings upgraded shares of Chemed from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. Finally, Wall Street Zen cut shares of Chemed from a “buy” rating to a “hold” rating in a research note on Monday, June 8th.

Insider Buying and Selling at Chemed

In related news, CEO Kevin J. Mcnamara sold 2,000 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $421.13, for a total value of $842,260.00. Following the completion of the sale, the chief executive officer owned 90,219 shares in the company, valued at $37,993,927.47. This trade represents a 2.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Andrea R. Lindell sold 1,347 shares of the firm’s stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $447.33, for a total transaction of $602,553.51. Following the completion of the sale, the director owned 4,578 shares of the company’s stock, valued at $2,047,876.74. This trade represents a 22.73% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.33% of the stock is currently owned by company insiders.

Institutional Trading of Chemed

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Maripau Wealth Management LLC lifted its stake in shares of Chemed by 5.4% in the first quarter. Maripau Wealth Management LLC now owns 970 shares of the company’s stock valued at $366,000 after purchasing an additional 50 shares during the period. Segall Bryant & Hamill LLC acquired a new stake in shares of Chemed in the first quarter valued at about $2,293,000. Cim LLC lifted its stake in shares of Chemed by 1.6% in the first quarter. Cim LLC now owns 2,325 shares of the company’s stock valued at $878,000 after purchasing an additional 37 shares during the period. Amundi lifted its stake in shares of Chemed by 6,982.7% in the first quarter. Amundi now owns 35,555 shares of the company’s stock valued at $13,431,000 after purchasing an additional 35,053 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of Chemed by 9.4% in the first quarter. EverSource Wealth Advisors LLC now owns 406 shares of the company’s stock valued at $153,000 after purchasing an additional 35 shares during the period. Institutional investors and hedge funds own 95.85% of the company’s stock.

Chemed Stock Up 2.2%

CHE stock opened at $432.70 on Wednesday. The company has a fifty day moving average price of $417.17 and a 200 day moving average price of $424.24. Chemed has a 12 month low of $365.20 and a 12 month high of $562.77. The company has a market cap of $5.74 billion, a price-to-earnings ratio of 23.58, a price-to-earnings-growth ratio of 1.59 and a beta of 0.54. The company has a debt-to-equity ratio of 0.11, a current ratio of 0.85 and a quick ratio of 0.83.

Chemed (NYSE:CHE) last released its quarterly earnings results on Thursday, April 23rd. The company reported $5.65 EPS for the quarter, beating the consensus estimate of $5.30 by $0.35. Chemed had a net margin of 10.23% and a return on equity of 27.18%. The firm had revenue of $657.51 million during the quarter, compared to the consensus estimate of $659.22 million. During the same quarter in the prior year, the firm earned $5.63 EPS. Chemed’s revenue for the quarter was up 1.6% on a year-over-year basis. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. Sell-side analysts expect that Chemed will post 22.3 earnings per share for the current year.

Chemed Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Thursday, May 28th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Thursday, May 28th. Chemed’s dividend payout ratio (DPR) is 13.08%.

Chemed Company Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.